01.10.2014 13:44:06

Isis Pharma Earns $1.5 Mln From GSK For The Advancement Of ISIS-GSK4 Rx

(RTTNews) - Isis Pharmaceuticals Inc. (ISIS) announced that it has earned a $1.5 million milestone payment from GSK related to the advancement of the program to develop ISIS-GSK4Rx to treat an undisclosed ocular disease.

"Our collaboration with GSK has been very productive resulting in four drugs in development. We look forward to advancing ISIS-GSK4Rx into clinical development and providing more information on the target and disease opportunity, which we are very excited about," said Lynne Parshall, chief operating officer at Isis.

Nachrichten zu ISIS Pharmaceuticals Inc.mehr Nachrichten

Keine Nachrichten verfügbar.

Analysen zu ISIS Pharmaceuticals Inc.mehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!